Plain-English translation of NCT06673329 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether , a medication already approved for skin conditions, might help patients whose cancer immunotherapy caused unwanted immune side effects. These side effects—called immune-related adverse events—happen when the body's immune system becomes overactive from treatment. Researchers want to see if this medication can safely reduce these side effects and allow patients to avoid or reduce steroid use.
Cancer immunotherapy is powerful but can trigger serious side effects as the immune system attacks the body's own tissues. Currently, steroids are the main way to manage these problems, but they come with their own risks. This trial is exploring whether this medication offers a safer or more effective way to control these immune side effects.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication under your skin at the start, then weekly for 2 weeks, and then every 2 weeks for a total of 24 weeks. You'll have office visits or telemedicine check-ins at weeks 1, 2, 4, and then every 4 weeks, with follow-up appointments at weeks 28 and 36. At each visit, blood will be drawn and you'll complete brief mood and safety questionnaires. Your doctor may reduce steroid doses gradually if your side effects improve.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States